Summary by Futu AI
Alterity Therapeutics, a development stage enterprise, has submitted its Corporate Governance Statement for the financial year ended June 30, 2024, as per the ASX Listing Rule 4.10.3. The statement, accurate as of September 26, 2024, outlines the company's adherence to the ASX Corporate Governance Council's Principles and Recommendations. It details the company's governance structure, including the roles and responsibilities of the Board and management, director appointments, performance reviews, and executive remuneration. The statement also addresses the company's commitment to ethical conduct, risk management, and the safeguarding of corporate reporting integrity. Alterity Therapeutics emphasizes the importance of diversity within its workforce, although it has not set specific measurable objectives for gender diversity due to the small size of its personnel. The company's Audit and Remuneration Committees are highlighted, along with their functions and the independence of their members. The statement further discusses the company's policies on communication, disclosure, shareholder rights, and remuneration, ensuring transparency and accountability in its operations.